These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Moore TD; Nawarskas JJ; Anderson JR Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. George J; Struthers AD Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264 [TBL] [Abstract][Full Text] [Related]
6. The role of aldosterone receptor blockade in the management of cardiovascular disease. Liew D; Krum H Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020 [TBL] [Abstract][Full Text] [Related]
7. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Barnes BJ; Howard PA Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870 [TBL] [Abstract][Full Text] [Related]
8. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876 [TBL] [Abstract][Full Text] [Related]
9. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Hameedi A; Chadow HL Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173 [TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T; Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190 [TBL] [Abstract][Full Text] [Related]
15. Eplerenone in the treatment of chronic heart failure. Krum H; Liew D Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479 [TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747 [TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists in heart failure. Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084 [TBL] [Abstract][Full Text] [Related]
18. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA). Coats AJ Int J Cardiol; 2001 Aug; 80(1):1-4. PubMed ID: 11532539 [TBL] [Abstract][Full Text] [Related]
19. The role of aldosterone receptor antagonists in the management of heart failure: an update. Nagarajan V; Chamsi-Pasha M; Tang WH Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344 [TBL] [Abstract][Full Text] [Related]